Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anticoagulants × Clear all
NCT00443573 2008-05-07

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

ARCA Biopharma, Inc.

Phase 1/2 Suspended
100 enrolled
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡